BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
Talmadge E. King, David A. Lynch(University of California, San Francisco), Kevin M. Brown(National Cancer Institute), Isabelle Leconte(Actelion (Switzerland)), Sébastiên Roux(Actelion (Switzerland)), Dominique Valeyre(Inserm), A. Morganti(Actelion (Switzerland)), Fernando Martínez(University of Michigan), Ganesh Raghu(University of Washington), Roland M. du Bois(Imperial College London)
Cited by 713
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
|Immunity|2009|2.3k
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
|The Lancet|2011|2.1k
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2006|1.3k